Literature DB >> 33384886

Testing Vision Is Not Testing For Vision.

Eli Peli1.   

Abstract

Visual prostheses aim to restore, at least to some extent, vision that leads to the type of perception available for sighted patients. Their effectiveness is almost always evaluated using clinical tests of vision. Clinical vision tests are designed to measure the limits of parameters of a functioning visual system. I argue here that these tests are rarely suited to determine the ability of prosthetic devices and other therapies to restore vision. This paper describes and explains many limitations of these evaluations. Prosthetic vision testing often makes use of multiple-alternative forced-choice (MAFC) procedures. Although these paradigms are suitable for many studies, they are frequently problematic in vision restoration evaluation. Two main types of problems are identified: (1) where nuisance variables provide spurious cues that can be learned in repeated training, which is common in prosthetic vision, and thus defeat the purpose of the test; and (2) even though a test is properly designed and performed, it may not actually measure what the researchers believe, and thus the interpretation of results is wrong. Examples for both types of problems are presented. Additional problems arise from confounding factors in the administration of tests are pointed as limitations of current device evaluation. For example, head tracing of magnified objects enlarged to compensate for the system's low resolution, in distinction from the scanning head (camera) movements with which users of prosthetic devices expand the limited field of view. Because of these problems, the ability to perform satisfactorily on the clinical tests is necessary but insufficient to prove vision restoration, therefore, additional tests are needed. I propose some directions to pursue in such testing. Translational Relevance: Numerous prosthetic devices are being developed and introduced to the market. Proving the utility of these devices is crucial for regulatory and even for post market acceptance, which so far has largely failed, in my opinion. Potential reasons for the failures despite success in regulatory testing and directions for designing improved testing are provided. It is hoped that improved testing will guide improved designs of future prosthetic systems and other vision restoration approaches. Copyright 2020 The Authors.

Entities:  

Keywords:  gene therapy; optogenetic; prosthetic vision; sensory substitution; spatial perception; stem cell; vision restoration; visual perception

Mesh:

Year:  2020        PMID: 33384886      PMCID: PMC7757632          DOI: 10.1167/tvst.9.13.32

Source DB:  PubMed          Journal:  Transl Vis Sci Technol        ISSN: 2164-2591            Impact factor:   3.283


  36 in total

1.  The Chicago face database: A free stimulus set of faces and norming data.

Authors:  Debbie S Ma; Joshua Correll; Bernd Wittenbrink
Journal:  Behav Res Methods       Date:  2015-12

2.  Word recognition: re-thinking prosthetic vision evaluation.

Authors:  Shui'Er Han; Cheng Qiu; Kassandra R Lee; Jae-Hyun Jung; Eli Peli
Journal:  J Neural Eng       Date:  2018-05-21       Impact factor: 5.379

3.  Tactile recognition of visual stimuli: Specificity versus generalization of perceptual learning.

Authors:  Gabriel Arnold; Malika Auvray
Journal:  Vision Res       Date:  2018-01-05       Impact factor: 1.886

4.  There is something out there: distal attribution in sensory substitution, twenty years later.

Authors:  Malika Auvray; Sylvain Hanneton; Charles Lenay; Kevin O'Regan
Journal:  J Integr Neurosci       Date:  2005-12       Impact factor: 2.117

5.  Eye Movement Control in the Argus II Retinal-Prosthesis Enables Reduced Head Movement and Better Localization Precision.

Authors:  Avi Caspi; Arup Roy; Varalakshmi Wuyyuru; Paul E Rosendall; Jason W Harper; Kapil D Katyal; Michael P Barry; Gislin Dagnelie; Robert J Greenberg
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-02-01       Impact factor: 4.799

6.  Gene therapy for red-green colour blindness in adult primates.

Authors:  Katherine Mancuso; William W Hauswirth; Qiuhong Li; Thomas B Connor; James A Kuchenbecker; Matthew C Mauck; Jay Neitz; Maureen Neitz
Journal:  Nature       Date:  2009-09-16       Impact factor: 49.962

Review 7.  Treating with spectacle lenses: a novel idea!?

Authors:  Eli Peli
Journal:  Optom Vis Sci       Date:  2002-09       Impact factor: 1.973

8.  Perceptual efficacy of electrical stimulation of human retina with a microelectrode array during short-term surgical trials.

Authors:  Joseph F Rizzo; John Wyatt; John Loewenstein; Shawn Kelly; Doug Shire
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-12       Impact factor: 4.799

9.  Basic quantitative assessment of visual performance in patients with very low vision.

Authors:  Michael Bach; Michaela Wilke; Barbara Wilhelm; Eberhart Zrenner; Robert Wilke
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-22       Impact factor: 4.799

10.  Artificial vision with wirelessly powered subretinal electronic implant alpha-IMS.

Authors:  Katarina Stingl; Karl Ulrich Bartz-Schmidt; Dorothea Besch; Angelika Braun; Anna Bruckmann; Florian Gekeler; Udo Greppmaier; Stephanie Hipp; Gernot Hörtdörfer; Christoph Kernstock; Assen Koitschev; Akos Kusnyerik; Helmut Sachs; Andreas Schatz; Krunoslav T Stingl; Tobias Peters; Barbara Wilhelm; Eberhart Zrenner
Journal:  Proc Biol Sci       Date:  2013-02-20       Impact factor: 5.349

View more
  2 in total

1.  Sequential epiretinal stimulation improves discrimination in simple shape discrimination tasks only.

Authors:  Breanne Christie; Roksana Sadeghi; Arathy Kartha; Avi Caspi; Francesco V Tenore; Roberta L Klatzky; Gislin Dagnelie; Seth Billings
Journal:  J Neural Eng       Date:  2022-06-09       Impact factor: 5.043

2.  Factors affecting two-point discrimination in Argus II patients.

Authors:  Ezgi I Yücel; Roksana Sadeghi; Arathy Kartha; Sandra Rocio Montezuma; Gislin Dagnelie; Ariel Rokem; Geoffrey M Boynton; Ione Fine; Michael Beyeler
Journal:  Front Neurosci       Date:  2022-08-24       Impact factor: 5.152

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.